You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameTriazolam
Accession NumberDB00897  (APRD00313)
TypeSmall Molecule
GroupsApproved
DescriptionWithdrawn in the United Kingdom due to risk of psychiatric adverse drug reactions. This drug continues to be available in the U.S. Internationally, triazolam is a Schedule IV drug under the Convention on Psychotropic Substances.
Structure
Thumb
Synonyms
Halcion
Triazolam
Triazolam
Triazolam
Triazolamum
External Identifiers
  • DEA No. 2887
  • U 33030
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Alti-triazolam Tab 0.125mgtablet.125 mgoralAltimed Pharma Inc.1987-12-312001-09-05Canada
Alti-triazolam Tab 0.25mgtablet.25 mgoralAltimed Pharma Inc.1987-12-312001-09-05Canada
Halciontablet.25 mg/1oralPharmacia and Upjohn Company1982-11-15Not applicableUs
Halciontablet0.125 mgoralPfizer Canada Inc1980-12-312006-08-02Canada
Halciontablet0.25 mgoralPfizer Canada Inc1978-12-312007-05-29Canada
Mylan-triazolamtablet0.125 mgoralMylan Pharmaceuticals Ulc1992-12-312011-03-04Canada
Mylan-triazolamtablet0.25 mgoralMylan Pharmaceuticals Ulc1992-12-312011-03-04Canada
Novo-triolam Tab 0.125mgtablet.125 mgoralNovopharm Limited1990-12-312005-08-10Canada
Novo-triolam Tab 0.25mgtablet.25 mgoralNovopharm Limited1990-12-312005-08-10Canada
Penta-triazolam Tabletstablet.25 mgoralPentapharm Ltd.Not applicableNot applicableCanada
Penta-triazolam Tabletstablet.125 mgoralPentapharm Ltd.Not applicableNot applicableCanada
Triazolamtablet0.25 mgoralAa Pharma Inc1989-12-31Not applicableCanada
Triazolamtablet.25 mg/1oralPd Rx Pharmaceuticals, Inc.1982-11-15Not applicableUs
Triazolamtablet.25 mg/1oralSTAT Rx USA LLC1982-11-15Not applicableUs
Triazolamtablet.125 mg/1oralGreenstone LLC1982-11-15Not applicableUs
Triazolamtablet0.125 mgoralAa Pharma Inc1989-12-312014-11-07Canada
Triazolamtablet.25 mg/1oralA S Medication Solutions Llc1982-11-15Not applicableUs
Triazolamtablet.25 mg/1oralGreenstone LLC1982-11-15Not applicableUs
Triazolamtablet.25 mg/1oralA S Medication Solutions Llc1982-11-15Not applicableUs
Triazolam Tab 0.125mgtablet.125 mgoralPro Doc Limitee1990-12-312009-07-23Canada
Triazolam Tab 0.25mgtablet.25 mgoralPro Doc Limitee1990-12-312009-07-23Canada
Triazolam Tablets 0.125mgtablet0.125 mgoralPrempharm Inc1997-01-052005-08-05Canada
Triazolam Tablets 0.25mgtablet0.25 mgoralPrempharm Inc1997-04-302005-08-05Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Triazolamtablet.25 mg/1oralA S Medication Solutions Llc1994-06-01Not applicableUs
Triazolamtablet.125 mg/1oralRoxane Laboratories, Inc.2009-07-13Not applicableUs
Triazolamtablet.125 mg/1oralRebel Distributors Corp2009-07-13Not applicableUs
Triazolamtablet.25 mg/1oralbryant ranch prepack1994-06-01Not applicableUs
Triazolamtablet.125 mg/1oralRoxane Laboratories, Inc.1994-06-01Not applicableUs
Triazolamtablet.25 mg/1oralLake Erie Medical DBA Quality Care Products LLC2011-06-01Not applicableUs
Triazolamtablet.25 mg/1oralAphena Pharma Solutions Tennessee, Inc.1994-06-01Not applicableUs
Triazolamtablet.25 mg/1oralRoxane Laboratories, Inc.1994-06-012016-01-30Us
Triazolamtablet.25 mg/1oralUnit Dose Services1994-06-01Not applicableUs
Triazolamtablet.25 mg/1oralPreferred Pharmaceuticals, Inc.2013-11-05Not applicableUs
Triazolamtablet.25 mg/1oralRebel Distributors Corp1994-06-01Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
Apo-TriazoApotex
ArringYungShin
AsasionChoseido Pharmaceutical Co., Ltd
AscomarnaNisshin Seiyaku K.K
SongarValeas S.p.A.
Brand mixturesNot Available
SaltsNot Available
Categories
UNII1HM943223R
CAS number28911-01-5
WeightAverage: 343.21
Monoisotopic: 342.043901818
Chemical FormulaC17H12Cl2N4
InChI KeyInChIKey=JOFWLTCLBGQGBO-UHFFFAOYSA-N
InChI
InChI=1S/C17H12Cl2N4/c1-10-21-22-16-9-20-17(12-4-2-3-5-14(12)19)13-8-11(18)6-7-15(13)23(10)16/h2-8H,9H2,1H3
IUPAC Name
12-chloro-9-(2-chlorophenyl)-3-methyl-2,4,5,8-tetraazatricyclo[8.4.0.0²,⁶]tetradeca-1(10),3,5,8,11,13-hexaene
SMILES
CC1=NN=C2CN=C(C3=CC=CC=C3Cl)C3=C(C=CC(Cl)=C3)N12
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as 1,4-benzodiazepines. These are organic compounds containing a benzene ring fused to a 1,4-azepine.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzodiazepines
Sub Class1,4-benzodiazepines
Direct Parent1,4-benzodiazepines
Alternative Parents
Substituents
  • 1,4-benzodiazepine
  • Phenyl-1,3,4-triazole
  • Phenyl-1,2,4-triazole
  • Phenyltriazole
  • Halobenzene
  • Chlorobenzene
  • Benzenoid
  • Monocyclic benzene moiety
  • Aryl halide
  • Aryl chloride
  • Heteroaromatic compound
  • 1,2,4-triazole
  • Triazole
  • Azole
  • Ketimine
  • Azacycle
  • Organic 1,3-dipolar compound
  • Propargyl-type 1,3-dipolar organic compound
  • Hydrocarbon derivative
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Imine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationFor the short-term treatment of insomnia.
PharmacodynamicsA short-acting benzodiazepine used as a hypnotic agent in the treatment of insomnia. Some countries temporarily withdrew triazolam from the market because of concerns about adverse reactions, mostly psychological, associated with higher dose ranges. Its use at lower doses with appropriate care and labeling has been reaffirmed by the FDA and most other countries. Triazolam has a shorter half-life than chlordiazepoxide, flurazepam, and prazepam and does not generate active metabolites.
Mechanism of actionBenzodiazepines bind nonspecifically to bezodiazepine receptors BNZ1, which mediates sleep, and BNZ2, which affects affects muscle relaxation, anticonvulsant activity, motor coordination, and memory. As benzodiazepine receptors are thought to be coupled to gamma-aminobutyric acid-A (GABAA) receptors, this enhances the effects of GABA by increasing GABA affinity for the GABA receptor. Binding of GABA to the site opens the chloride channel, resulting in a hyperpolarized cell membrane that prevents further excitation of the cell.
Related Articles
AbsorptionBioavailability is 44% (oral) and 53% (sublingual).
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Hepatic. Small amounts of unmetabolized triazolam appear in the urine.

SubstrateEnzymesProduct
Triazolam
4-hydroxytriazolamDetails
Triazolam
1'-hydroxytriazolamDetails
Route of eliminationTriazolam and its metabolites, principally as conjugated glucuronides, which are presumably inactive, are excreted primarily in the urine. Only small amounts of unmetabolized triazolam appear in the urine. The two primary metabolites accounted for 79.9% of urinary excretion.
Half life1.5-5.5 hours
ClearanceNot Available
ToxicitySymptoms of overdose include drowsiness, slurred speech, motor inco-ordination, coma, and respiratory depression.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9719
Caco-2 permeable+0.886
P-glycoprotein substrateNon-substrate0.5252
P-glycoprotein inhibitor INon-inhibitor0.6788
P-glycoprotein inhibitor IIInhibitor0.8331
Renal organic cation transporterInhibitor0.7628
CYP450 2C9 substrateNon-substrate0.7898
CYP450 2D6 substrateNon-substrate0.9208
CYP450 3A4 substrateSubstrate0.751
CYP450 1A2 substrateInhibitor0.8598
CYP450 2C9 inhibitorInhibitor0.815
CYP450 2D6 inhibitorNon-inhibitor0.8226
CYP450 2C19 inhibitorInhibitor0.7117
CYP450 3A4 inhibitorNon-inhibitor0.5596
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.9088
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.6714
BiodegradationNot ready biodegradable1.0
Rat acute toxicity1.9971 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9638
hERG inhibition (predictor II)Non-inhibitor0.8806
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Pharmacia and upjohn co
  • Alphapharm party ltd
  • Roxane laboratories inc
  • Watson laboratories inc
Packagers
Dosage forms
FormRouteStrength
Tabletoral.25 mg/1
Tabletoral0.125 mg
Tabletoral.125 mg
Tabletoral.25 mg
Tabletoral.125 mg/1
Tabletoral0.25 mg
Prices
Unit descriptionCostUnit
Halcion 10 0.25 mg tablet Bottle21.0USD bottle
Triazolam 10 0.125 mg tablet Bottle6.33USD bottle
Triazolam 10 0.25 mg tablet Bottle6.0USD bottle
Halcion 0.25 mg tablet1.99USD tablet
Halcion 0.125 mg tablet1.37USD tablet
Triazolam 0.25 mg tablet0.67USD tablet
Triazolam 0.125 mg tablet0.65USD tablet
Apo-Triazo 0.25 mg Tablet0.22USD tablet
Mylan-Triazolam 0.25 mg Tablet0.22USD tablet
Apo-Triazo 0.125 mg Tablet0.12USD tablet
Mylan-Triazolam 0.125 mg Tablet0.12USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point233-235 °CNot Available
water solubility4.53 mg/LNot Available
logP2.42BIOBYTE (1995)
logS-4.08ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.0183 mg/mLALOGPS
logP2.94ALOGPS
logP2.89ChemAxon
logS-4.3ALOGPS
pKa (Strongest Acidic)18.08ChemAxon
pKa (Strongest Basic)4.32ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area43.07 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity103.68 m3·mol-1ChemAxon
Polarizability34.19 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-0imr-4954000000-75bcea16a1182103168fView in MoNA
References
Synthesis ReferenceNot Available
General References
  1. Rickels K: The clinical use of hypnotics: indications for use and the need for a variety of hypnotics. Acta Psychiatr Scand Suppl. 1986;332:132-41. [PubMed:2883820 ]
  2. Oelschlager H: [Chemical and pharmacologic aspects of benzodiazepines]. Schweiz Rundsch Med Prax. 1989 Jul 4;78(27-28):766-72. [PubMed:2570451 ]
  3. Noguchi H, Kitazumi K, Mori M, Shiba T: Electroencephalographic properties of zaleplon, a non-benzodiazepine sedative/hypnotic, in rats. J Pharmacol Sci. 2004 Mar;94(3):246-51. [PubMed:15037809 ]
  4. Tokunaga S, Takeda Y, Shinomiya K, Hirase M, Kamei C: Effects of some H1-antagonists on the sleep-wake cycle in sleep-disturbed rats. J Pharmacol Sci. 2007 Feb;103(2):201-6. Epub 2007 Feb 8. [PubMed:17287588 ]
  5. Veje JO, Andersen K, Gjesing S, Kielgast H: [Prescription of tranquilizers and hypnotics in the municipality of Holbaek]. Ugeskr Laeger. 1989 Aug 21;151(34):2134-6. [PubMed:2773144 ]
External Links
ATC CodesN05CD05
AHFS Codes
  • 28:24.08
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (5.44 KB)
Interactions
Drug Interactions
Drug
1,10-PhenanthrolineThe serum concentration of Triazolam can be increased when it is combined with 1,10-Phenanthroline.
3,4-DichloroisocoumarinThe serum concentration of Triazolam can be increased when it is combined with 3,4-Dichloroisocoumarin.
4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDEThe serum concentration of Triazolam can be increased when it is combined with 4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDE.
7-NitroindazoleThe risk or severity of adverse effects can be increased when Triazolam is combined with 7-Nitroindazole.
AcepromazineThe risk or severity of adverse effects can be increased when Triazolam is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Triazolam is combined with Aceprometazine.
adipiplonThe risk or severity of adverse effects can be increased when Triazolam is combined with adipiplon.
AgomelatineThe risk or severity of adverse effects can be increased when Triazolam is combined with Agomelatine.
AlfaxaloneThe risk or severity of adverse effects can be increased when Triazolam is combined with Alfaxalone.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Triazolam.
AlogliptinThe serum concentration of Triazolam can be increased when it is combined with Alogliptin.
Alpha-1-proteinase inhibitorThe serum concentration of Triazolam can be increased when it is combined with Alpha-1-proteinase inhibitor.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Triazolam is combined with Alphacetylmethadol.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Triazolam.
AminophyllineThe therapeutic efficacy of Triazolam can be decreased when used in combination with Aminophylline.
AmiodaroneThe metabolism of Triazolam can be decreased when combined with Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Triazolam is combined with Amisulpride.
AmitriptylineThe risk or severity of adverse effects can be increased when Triazolam is combined with Amitriptyline.
AmobarbitalThe risk or severity of adverse effects can be increased when Triazolam is combined with Amobarbital.
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Triazolam.
AmoxapineThe risk or severity of adverse effects can be increased when Triazolam is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Triazolam is combined with Amperozide.
AmprenavirThe serum concentration of Triazolam can be increased when it is combined with Amprenavir.
Antithrombin III humanThe serum concentration of Triazolam can be increased when it is combined with Antithrombin III human.
ApixabanThe serum concentration of Triazolam can be increased when it is combined with Apixaban.
AprepitantThe serum concentration of Triazolam can be increased when it is combined with Aprepitant.
AprotininThe serum concentration of Triazolam can be increased when it is combined with Aprotinin.
ArgatrobanThe serum concentration of Triazolam can be increased when it is combined with Argatroban.
AripiprazoleThe risk or severity of adverse effects can be increased when Triazolam is combined with Aripiprazole.
ArticaineThe risk or severity of adverse effects can be increased when Triazolam is combined with Articaine.
AsenapineThe risk or severity of adverse effects can be increased when Triazolam is combined with Asenapine.
AsunaprevirThe serum concentration of Triazolam can be increased when it is combined with Asunaprevir.
AtazanavirThe serum concentration of Triazolam can be increased when it is combined with Atazanavir.
AtomoxetineThe metabolism of Triazolam can be decreased when combined with Atomoxetine.
AzaperoneThe risk or severity of adverse effects can be increased when Triazolam is combined with Azaperone.
AzelastineTriazolam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Triazolam.
BaclofenThe risk or severity of adverse effects can be increased when Triazolam is combined with Baclofen.
BarbitalThe risk or severity of adverse effects can be increased when Triazolam is combined with Barbital.
BatimastatThe serum concentration of Triazolam can be increased when it is combined with Batimastat.
BenazeprilThe serum concentration of Triazolam can be increased when it is combined with Benazepril.
BenzamidineThe serum concentration of Triazolam can be increased when it is combined with Benzamidine.
BenzocaineThe risk or severity of adverse effects can be increased when Triazolam is combined with Benzocaine.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Triazolam is combined with Benzyl alcohol.
BexaroteneThe serum concentration of Triazolam can be decreased when it is combined with Bexarotene.
BivalirudinThe serum concentration of Triazolam can be increased when it is combined with Bivalirudin.
BoceprevirThe serum concentration of Triazolam can be increased when it is combined with Boceprevir.
BortezomibThe metabolism of Triazolam can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Triazolam can be decreased when it is combined with Bosentan.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Triazolam is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Triazolam.
BrimonidineThe risk or severity of adverse effects can be increased when Triazolam is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Triazolam is combined with Bromazepam.
BrompheniramineThe risk or severity of adverse effects can be increased when Triazolam is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Brotizolam.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Triazolam.
BuprenorphineThe risk or severity of adverse effects can be increased when Triazolam is combined with Buprenorphine.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Triazolam.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Triazolam.
ButacaineThe risk or severity of adverse effects can be increased when Triazolam is combined with Butacaine.
ButalbitalThe risk or severity of adverse effects can be increased when Triazolam is combined with Butalbital.
ButambenThe risk or severity of adverse effects can be increased when Triazolam is combined with Butamben.
ButethalThe risk or severity of adverse effects can be increased when Triazolam is combined with Butethal.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Triazolam.
CandoxatrilThe serum concentration of Triazolam can be increased when it is combined with Candoxatril.
CaptoprilThe serum concentration of Triazolam can be increased when it is combined with Captopril.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Triazolam.
CarbinoxamineThe risk or severity of adverse effects can be increased when Triazolam is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Triazolam is combined with Carfentanil.
CarisoprodolThe risk or severity of adverse effects can be increased when Triazolam is combined with Carisoprodol.
CeritinibThe serum concentration of Triazolam can be increased when it is combined with Ceritinib.
CetirizineThe risk or severity of adverse effects can be increased when Triazolam is combined with Cetirizine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Triazolam is combined with Chloral hydrate.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Triazolam.
ChlormezanoneThe risk or severity of adverse effects can be increased when Triazolam is combined with Chlormezanone.
ChloroprocaineThe risk or severity of adverse effects can be increased when Triazolam is combined with Chloroprocaine.
ChlorphenamineThe risk or severity of adverse effects can be increased when Triazolam is combined with Chlorphenamine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Triazolam.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Triazolam is combined with Chlorprothixene.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Triazolam is combined with Chlorzoxazone.
ChymostatinThe serum concentration of Triazolam can be increased when it is combined with Chymostatin.
CilastatinThe serum concentration of Triazolam can be increased when it is combined with Cilastatin.
CilazaprilThe serum concentration of Triazolam can be increased when it is combined with Cilazapril.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Triazolam.
CitalopramThe risk or severity of adverse effects can be increased when Triazolam is combined with Citalopram.
ClarithromycinThe metabolism of Triazolam can be decreased when combined with Clarithromycin.
ClemastineThe metabolism of Triazolam can be decreased when combined with Clemastine.
ClemastineThe risk or severity of adverse effects can be increased when Triazolam is combined with Clemastine.
ClidiniumThe risk or severity of adverse effects can be increased when Triazolam is combined with Clidinium.
ClobazamThe risk or severity of adverse effects can be increased when Triazolam is combined with Clobazam.
clomethiazoleThe risk or severity of adverse effects can be increased when Triazolam is combined with clomethiazole.
ClomipramineThe risk or severity of adverse effects can be increased when Triazolam is combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Triazolam is combined with Clonazepam.
ClonidineThe risk or severity of adverse effects can be increased when Triazolam is combined with Clonidine.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Triazolam.
ClotrimazoleThe metabolism of Triazolam can be decreased when combined with Clotrimazole.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Triazolam.
CobicistatThe serum concentration of Triazolam can be increased when it is combined with Cobicistat.
CocaineThe risk or severity of adverse effects can be increased when Triazolam is combined with Cocaine.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Triazolam.
ConivaptanThe serum concentration of Triazolam can be increased when it is combined with Conivaptan.
CrizotinibThe metabolism of Triazolam can be decreased when combined with Crizotinib.
CyclizineThe risk or severity of adverse effects can be increased when Triazolam is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Triazolam is combined with Cyclobenzaprine.
CyclosporineThe metabolism of Triazolam can be decreased when combined with Cyclosporine.
CyproheptadineThe risk or severity of adverse effects can be increased when Triazolam is combined with Cyproheptadine.
Dabigatran etexilateThe serum concentration of Triazolam can be increased when it is combined with Dabigatran etexilate.
DabrafenibThe serum concentration of Triazolam can be decreased when it is combined with Dabrafenib.
DantroleneThe risk or severity of adverse effects can be increased when Triazolam is combined with Dantrolene.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Triazolam.
DapoxetineThe risk or severity of adverse effects can be increased when Triazolam is combined with Dapoxetine.
DarunavirThe serum concentration of Triazolam can be increased when it is combined with Darunavir.
DasatinibThe serum concentration of Triazolam can be increased when it is combined with Dasatinib.
DeferasiroxThe serum concentration of Triazolam can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Triazolam can be decreased when combined with Delavirdine.
deramciclaneThe risk or severity of adverse effects can be increased when Triazolam is combined with deramciclane.
DesfluraneThe risk or severity of adverse effects can be increased when Triazolam is combined with Desflurane.
DesipramineThe risk or severity of adverse effects can be increased when Triazolam is combined with Desipramine.
DesloratadineThe risk or severity of adverse effects can be increased when Triazolam is combined with Desloratadine.
DetomidineThe risk or severity of adverse effects can be increased when Triazolam is combined with Detomidine.
DexamethasoneThe serum concentration of Triazolam can be decreased when it is combined with Dexamethasone.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Triazolam is combined with Dexbrompheniramine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Triazolam.
DextromoramideThe risk or severity of adverse effects can be increased when Triazolam is combined with Dextromoramide.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Triazolam.
DezocineThe risk or severity of adverse effects can be increased when Triazolam is combined with Dezocine.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Triazolam.
DifenoxinThe risk or severity of adverse effects can be increased when Triazolam is combined with Difenoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Triazolam is combined with Dihydrocodeine.
DihydroergotamineThe metabolism of Triazolam can be decreased when combined with Dihydroergotamine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Triazolam is combined with Dihydroetorphine.
DihydromorphineThe risk or severity of adverse effects can be increased when Triazolam is combined with Dihydromorphine.
DiltiazemThe metabolism of Triazolam can be decreased when combined with Diltiazem.
DimenhydrinateThe risk or severity of adverse effects can be increased when Triazolam is combined with Dimenhydrinate.
DiphenhydramineThe risk or severity of adverse effects can be increased when Triazolam is combined with Diphenhydramine.
DiphenoxylateThe risk or severity of adverse effects can be increased when Triazolam is combined with Diphenoxylate.
DoramectinThe risk or severity of adverse effects can be increased when Triazolam is combined with Doramectin.
DoxepinThe risk or severity of adverse effects can be increased when Triazolam is combined with Doxepin.
DoxycyclineThe metabolism of Triazolam can be decreased when combined with Doxycycline.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Triazolam.
DoxylamineThe risk or severity of adverse effects can be increased when Triazolam is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when Triazolam is combined with DPDPE.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Triazolam.
DronedaroneThe metabolism of Triazolam can be decreased when combined with Dronedarone.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Triazolam.
DrotebanolThe risk or severity of adverse effects can be increased when Triazolam is combined with Drotebanol.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Triazolam.
DyphyllineThe therapeutic efficacy of Triazolam can be decreased when used in combination with Dyphylline.
EcabetThe serum concentration of Triazolam can be increased when it is combined with Ecabet.
EcgonineThe risk or severity of adverse effects can be increased when Triazolam is combined with Ecgonine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Triazolam is combined with ECGONINE METHYL ESTER.
EdoxabanThe serum concentration of Triazolam can be increased when it is combined with Edoxaban.
EfavirenzThe serum concentration of Triazolam can be decreased when it is combined with Efavirenz.
EfavirenzThe risk or severity of adverse effects can be increased when Triazolam is combined with Efavirenz.
ElafinThe serum concentration of Triazolam can be increased when it is combined with Elafin.
EnalaprilThe serum concentration of Triazolam can be increased when it is combined with Enalapril.
EnalaprilatThe serum concentration of Triazolam can be increased when it is combined with Enalaprilat.
EnalkirenThe serum concentration of Triazolam can be increased when it is combined with Enalkiren.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Triazolam.
EntacaponeThe risk or severity of adverse effects can be increased when Triazolam is combined with Entacapone.
EnzalutamideThe serum concentration of Triazolam can be decreased when it is combined with Enzalutamide.
ErythromycinThe metabolism of Triazolam can be decreased when combined with Erythromycin.
EscitalopramThe risk or severity of adverse effects can be increased when Triazolam is combined with Escitalopram.
Eslicarbazepine acetateThe serum concentration of Triazolam can be decreased when it is combined with Eslicarbazepine acetate.
EstazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Estazolam.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Triazolam.
EthanolTriazolam may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Triazolam.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Triazolam.
EthosuximideThe risk or severity of adverse effects can be increased when Triazolam is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Triazolam is combined with Ethotoin.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Triazolam is combined with Ethyl carbamate.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Triazolam is combined with Ethyl loflazepate.
EthylmorphineThe risk or severity of adverse effects can be increased when Triazolam is combined with Ethylmorphine.
EtidocaineThe risk or severity of adverse effects can be increased when Triazolam is combined with Etidocaine.
EtifoxineThe risk or severity of adverse effects can be increased when Triazolam is combined with Etifoxine.
EtizolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Etizolam.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Triazolam.
EtoperidoneThe risk or severity of adverse effects can be increased when Triazolam is combined with Etoperidone.
EtorphineThe risk or severity of adverse effects can be increased when Triazolam is combined with Etorphine.
EtravirineThe serum concentration of Triazolam can be decreased when it is combined with Etravirine.
EzogabineThe risk or severity of adverse effects can be increased when Triazolam is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Triazolam is combined with Felbamate.
FencamfamineThe risk or severity of adverse effects can be increased when Triazolam is combined with Fencamfamine.
FenfluramineThe risk or severity of adverse effects can be increased when Triazolam is combined with Fenfluramine.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Triazolam.
FexofenadineThe risk or severity of adverse effects can be increased when Triazolam is combined with Fexofenadine.
FlibanserinThe risk or severity of adverse effects can be increased when Triazolam is combined with Flibanserin.
FluconazoleThe metabolism of Triazolam can be decreased when combined with Fluconazole.
FludiazepamThe risk or severity of adverse effects can be increased when Triazolam is combined with Fludiazepam.
FlunarizineThe risk or severity of adverse effects can be increased when Triazolam is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Triazolam is combined with Flunitrazepam.
FluoxetineThe risk or severity of adverse effects can be increased when Triazolam is combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Triazolam.
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Triazolam.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Triazolam.
FluspirileneThe risk or severity of adverse effects can be increased when Triazolam is combined with Fluspirilene.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Triazolam is combined with Fluticasone Propionate.
FluvoxamineThe risk or severity of adverse effects can be increased when Triazolam is combined with Fluvoxamine.
FluvoxamineThe metabolism of Triazolam can be decreased when combined with Fluvoxamine.
FosamprenavirThe serum concentration of Triazolam can be increased when it is combined with Fosamprenavir.
FosaprepitantThe serum concentration of Triazolam can be increased when it is combined with Fosaprepitant.
FosinoprilThe serum concentration of Triazolam can be increased when it is combined with Fosinopril.
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Triazolam.
FosphenytoinThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Triazolam.
FospropofolThe risk or severity of adverse effects can be increased when Triazolam is combined with Fospropofol.
Fusidic AcidThe serum concentration of Triazolam can be increased when it is combined with Fusidic Acid.
GabapentinThe risk or severity of adverse effects can be increased when Triazolam is combined with Gabapentin.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Triazolam is combined with gabapentin enacarbil.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Triazolam is combined with Gamma Hydroxybutyric Acid.
GeldanamycinThe serum concentration of Triazolam can be increased when it is combined with Geldanamycin.
GlutethimideThe risk or severity of adverse effects can be increased when Triazolam is combined with Glutethimide.
GM6001The serum concentration of Triazolam can be increased when it is combined with GM6001.
GuanfacineThe risk or severity of adverse effects can be increased when Triazolam is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Triazolam.
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Triazolam.
HalothaneThe risk or severity of adverse effects can be increased when Triazolam is combined with Halothane.
HeroinThe risk or severity of adverse effects can be increased when Triazolam is combined with Heroin.
HexobarbitalThe risk or severity of adverse effects can be increased when Triazolam is combined with Hexobarbital.
HirulogThe serum concentration of Triazolam can be increased when it is combined with Hirulog.
HydrocodoneThe risk or severity of adverse effects can be increased when Triazolam is combined with Hydrocodone.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Triazolam.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Triazolam.
HydroxyzineThe risk or severity of adverse effects can be increased when Triazolam is combined with Hydroxyzine.
IdelalisibThe serum concentration of Triazolam can be increased when it is combined with Idelalisib.
IloperidoneThe risk or severity of adverse effects can be increased when Triazolam is combined with Iloperidone.
ImatinibThe metabolism of Triazolam can be decreased when combined with Imatinib.
ImipramineThe risk or severity of adverse effects can be increased when Triazolam is combined with Imipramine.
IndalpineThe risk or severity of adverse effects can be increased when Triazolam is combined with Indalpine.
IndinavirThe serum concentration of Triazolam can be increased when it is combined with Indinavir.
IsavuconazoniumThe metabolism of Triazolam can be decreased when combined with Isavuconazonium.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Triazolam.
IsoflurophateThe serum concentration of Triazolam can be increased when it is combined with Isoflurophate.
IsradipineThe metabolism of Triazolam can be decreased when combined with Isradipine.
ItraconazoleThe serum concentration of Triazolam can be increased when it is combined with Itraconazole.
IvacaftorThe serum concentration of Triazolam can be increased when it is combined with Ivacaftor.
IxazomibThe serum concentration of Triazolam can be increased when it is combined with Ixazomib.
KetamineThe risk or severity of adverse effects can be increased when Triazolam is combined with Ketamine.
KetazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Ketazolam.
KetobemidoneThe risk or severity of adverse effects can be increased when Triazolam is combined with Ketobemidone.
KetoconazoleThe serum concentration of Triazolam can be increased when it is combined with Ketoconazole.
LamotrigineThe risk or severity of adverse effects can be increased when Triazolam is combined with Lamotrigine.
LepirudinThe serum concentration of Triazolam can be increased when it is combined with Lepirudin.
LevetiracetamThe risk or severity of adverse effects can be increased when Triazolam is combined with Levetiracetam.
LevobupivacaineThe risk or severity of adverse effects can be increased when Triazolam is combined with Levobupivacaine.
LevocabastineThe risk or severity of adverse effects can be increased when Triazolam is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Triazolam is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Triazolam is combined with Levodopa.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Triazolam is combined with Levomethadyl Acetate.
LevomilnacipranThe risk or severity of adverse effects can be increased when Triazolam is combined with Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Triazolam.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Triazolam.
LinagliptinThe serum concentration of Triazolam can be increased when it is combined with Linagliptin.
LisinoprilThe serum concentration of Triazolam can be increased when it is combined with Lisinopril.
LithiumThe risk or severity of adverse effects can be increased when Triazolam is combined with Lithium.
LofentanilThe risk or severity of adverse effects can be increased when Triazolam is combined with Lofentanil.
LopinavirThe serum concentration of Triazolam can be increased when it is combined with Lopinavir.
LoratadineThe risk or severity of adverse effects can be increased when Triazolam is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Triazolam.
LovastatinThe metabolism of Triazolam can be decreased when combined with Lovastatin.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Triazolam.
Lu AA21004The risk or severity of adverse effects can be increased when Triazolam is combined with Lu AA21004.
LuliconazoleThe serum concentration of Triazolam can be increased when it is combined with Luliconazole.
LurasidoneThe risk or severity of adverse effects can be increased when Triazolam is combined with Lurasidone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Triazolam.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Triazolam is combined with Magnesium Sulfate.
MaprotilineThe risk or severity of adverse effects can be increased when Triazolam is combined with Maprotiline.
MeclizineThe risk or severity of adverse effects can be increased when Triazolam is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Triazolam is combined with Medetomidine.
MelatoninThe risk or severity of adverse effects can be increased when Triazolam is combined with Melatonin.
MelperoneThe risk or severity of adverse effects can be increased when Triazolam is combined with Melperone.
MepivacaineThe risk or severity of adverse effects can be increased when Triazolam is combined with Mepivacaine.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Triazolam.
MesoridazineThe risk or severity of adverse effects can be increased when Triazolam is combined with Mesoridazine.
MetaxaloneThe risk or severity of adverse effects can be increased when Triazolam is combined with Metaxalone.
MethadoneTriazolam may increase the central nervous system depressant (CNS depressant) activities of Methadone.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Triazolam.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Triazolam is combined with Methadyl Acetate.
MethapyrileneThe risk or severity of adverse effects can be increased when Triazolam is combined with Methapyrilene.
MethaqualoneThe risk or severity of adverse effects can be increased when Triazolam is combined with Methaqualone.
MethocarbamolThe risk or severity of adverse effects can be increased when Triazolam is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Triazolam.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Triazolam is combined with Methotrimeprazine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Triazolam is combined with Methoxyflurane.
MethsuximideThe risk or severity of adverse effects can be increased when Triazolam is combined with Methsuximide.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Triazolam.
MetyrosineTriazolam may increase the sedative activities of Metyrosine.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Triazolam.
MifepristoneThe metabolism of Triazolam can be decreased when combined with Mifepristone.
MilnacipranThe risk or severity of adverse effects can be increased when Triazolam is combined with Milnacipran.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Triazolam.
MirtazapineTriazolam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Triazolam.
MitotaneThe serum concentration of Triazolam can be decreased when it is combined with Mitotane.
ModafinilThe serum concentration of Triazolam can be decreased when it is combined with Modafinil.
MoexiprilThe serum concentration of Triazolam can be increased when it is combined with Moexipril.
MolindoneThe risk or severity of adverse effects can be increased when Triazolam is combined with Molindone.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Triazolam.
N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-ProlineThe serum concentration of Triazolam can be increased when it is combined with N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Triazolam.
NabiloneThe risk or severity of adverse effects can be increased when Triazolam is combined with Nabilone.
NafcillinThe serum concentration of Triazolam can be decreased when it is combined with Nafcillin.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Triazolam.
NCX 4016The serum concentration of Triazolam can be increased when it is combined with NCX 4016.
NefazodoneThe metabolism of Triazolam can be decreased when combined with Nefazodone.
NelfinavirThe serum concentration of Triazolam can be increased when it is combined with Nelfinavir.
NetupitantThe serum concentration of Triazolam can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Triazolam can be decreased when combined with Nevirapine.
NilotinibThe metabolism of Triazolam can be decreased when combined with Nilotinib.
NitrazepamThe risk or severity of adverse effects can be increased when Triazolam is combined with Nitrazepam.
Nitrous oxideThe risk or severity of adverse effects can be increased when Triazolam is combined with Nitrous oxide.
NormethadoneThe risk or severity of adverse effects can be increased when Triazolam is combined with Normethadone.
NortriptylineThe risk or severity of adverse effects can be increased when Triazolam is combined with Nortriptyline.
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Triazolam.
OlaparibThe metabolism of Triazolam can be decreased when combined with Olaparib.
OlopatadineThe risk or severity of adverse effects can be increased when Triazolam is combined with Olopatadine.
OmapatrilatThe serum concentration of Triazolam can be increased when it is combined with Omapatrilat.
OndansetronThe risk or severity of adverse effects can be increased when Triazolam is combined with Ondansetron.
OpiumThe risk or severity of adverse effects can be increased when Triazolam is combined with Opium.
OrphenadrineTriazolam may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Triazolam.
OsanetantThe risk or severity of adverse effects can be increased when Triazolam is combined with Osanetant.
OsimertinibThe serum concentration of Triazolam can be increased when it is combined with Osimertinib.
OtamixabanThe serum concentration of Triazolam can be increased when it is combined with Otamixaban.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Triazolam.
OxprenololThe risk or severity of adverse effects can be increased when Triazolam is combined with Oxprenolol.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Triazolam.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Triazolam.
OxymorphoneThe risk or severity of adverse effects can be increased when Triazolam is combined with Oxymorphone.
PalbociclibThe serum concentration of Triazolam can be increased when it is combined with Palbociclib.
PaliperidoneThe risk or severity of adverse effects can be increased when Triazolam is combined with Paliperidone.
ParaldehydeTriazolam may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Triazolam.
ParoxetineThe risk or severity of adverse effects can be increased when Triazolam is combined with Paroxetine.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Triazolam.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Triazolam.
PerampanelThe risk or severity of adverse effects can be increased when Triazolam is combined with Perampanel.
PerindoprilThe serum concentration of Triazolam can be increased when it is combined with Perindopril.
PerospironeThe risk or severity of adverse effects can be increased when Triazolam is combined with Perospirone.
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Triazolam.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Triazolam.
PhenobarbitalThe risk or severity of adverse effects can be increased when Triazolam is combined with Phenobarbital.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Triazolam is combined with Phenoxyethanol.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Triazolam.
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Triazolam.
PhosphoramidonThe serum concentration of Triazolam can be increased when it is combined with Phosphoramidon.
PimozideThe risk or severity of adverse effects can be increased when Triazolam is combined with Pimozide.
PipamperoneThe risk or severity of adverse effects can be increased when Triazolam is combined with Pipamperone.
PipotiazineThe risk or severity of adverse effects can be increased when Triazolam is combined with Pipotiazine.
PizotifenThe risk or severity of adverse effects can be increased when Triazolam is combined with Pizotifen.
PomalidomideThe risk or severity of adverse effects can be increased when Triazolam is combined with Pomalidomide.
PosaconazoleThe metabolism of Triazolam can be decreased when combined with Posaconazole.
PramipexoleTriazolam may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Triazolam is combined with Pramocaine.
PrazepamThe risk or severity of adverse effects can be increased when Triazolam is combined with Prazepam.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Triazolam.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Triazolam.
PrimidoneThe risk or severity of adverse effects can be increased when Triazolam is combined with Primidone.
PrinomastatThe serum concentration of Triazolam can be increased when it is combined with Prinomastat.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Triazolam.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Triazolam.
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Triazolam.
PromethazineThe risk or severity of adverse effects can be increased when Triazolam is combined with Promethazine.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Triazolam.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Triazolam.
PropoxycaineThe risk or severity of adverse effects can be increased when Triazolam is combined with Propoxycaine.
ProtriptylineThe risk or severity of adverse effects can be increased when Triazolam is combined with Protriptyline.
PSD502The risk or severity of adverse effects can be increased when Triazolam is combined with PSD502.
QuazepamThe risk or severity of adverse effects can be increased when Triazolam is combined with Quazepam.
QuetiapineThe risk or severity of adverse effects can be increased when Triazolam is combined with Quetiapine.
QuinaprilThe serum concentration of Triazolam can be increased when it is combined with Quinapril.
RamelteonThe risk or severity of adverse effects can be increased when Triazolam is combined with Ramelteon.
RamiprilThe serum concentration of Triazolam can be increased when it is combined with Ramipril.
RanolazineThe metabolism of Triazolam can be decreased when combined with Ranolazine.
RemifentanilThe risk or severity of adverse effects can be increased when Triazolam is combined with Remifentanil.
RemikirenThe serum concentration of Triazolam can be increased when it is combined with Remikiren.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Triazolam.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Triazolam.
RifabutinThe metabolism of Triazolam can be increased when combined with Rifabutin.
RifampicinThe metabolism of Triazolam can be increased when combined with Rifampicin.
RifapentineThe metabolism of Triazolam can be increased when combined with Rifapentine.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Triazolam.
RitonavirThe serum concentration of Triazolam can be increased when it is combined with Ritonavir.
RivaroxabanThe serum concentration of Triazolam can be increased when it is combined with Rivaroxaban.
RomifidineThe risk or severity of adverse effects can be increased when Triazolam is combined with Romifidine.
RopiniroleTriazolam may increase the sedative activities of Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Triazolam.
RotigotineTriazolam may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Triazolam.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Triazolam is combined with S-Ethylisothiourea.
SaquinavirThe serum concentration of Triazolam can be increased when it is combined with Saquinavir.
SaxagliptinThe serum concentration of Triazolam can be increased when it is combined with Saxagliptin.
ScopolamineThe risk or severity of adverse effects can be increased when Triazolam is combined with Scopolamine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Triazolam.
SertindoleThe risk or severity of adverse effects can be increased when Triazolam is combined with Sertindole.
SertralineThe risk or severity of adverse effects can be increased when Triazolam is combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Triazolam is combined with Sevoflurane.
SildenafilThe metabolism of Triazolam can be decreased when combined with Sildenafil.
SiltuximabThe serum concentration of Triazolam can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Triazolam can be increased when it is combined with Simeprevir.
SitagliptinThe serum concentration of Triazolam can be increased when it is combined with Sitagliptin.
Sodium oxybateTriazolam may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.
Sodium oxybateThe risk or severity of adverse effects can be increased when Sodium oxybate is combined with Triazolam.
SpiraprilThe serum concentration of Triazolam can be increased when it is combined with Spirapril.
St. John's WortThe serum concentration of Triazolam can be decreased when it is combined with St. John's Wort.
StiripentolThe risk or severity of adverse effects can be increased when Triazolam is combined with Stiripentol.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Triazolam.
SulfisoxazoleThe metabolism of Triazolam can be decreased when combined with Sulfisoxazole.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Triazolam.
SuvorexantThe risk or severity of adverse effects can be increased when Triazolam is combined with Suvorexant.
TapentadolThe risk or severity of adverse effects can be increased when Triazolam is combined with Tapentadol.
TasimelteonThe risk or severity of adverse effects can be increased when Triazolam is combined with Tasimelteon.
TeduglutideThe serum concentration of Triazolam can be increased when it is combined with Teduglutide.
TelaprevirThe serum concentration of Triazolam can be increased when it is combined with Telaprevir.
TelithromycinThe metabolism of Triazolam can be decreased when combined with Telithromycin.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Triazolam.
TemocaprilThe serum concentration of Triazolam can be increased when it is combined with Temocapril.
TetrabenazineThe risk or severity of adverse effects can be increased when Triazolam is combined with Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Triazolam is combined with Tetracaine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Triazolam is combined with Tetrodotoxin.
ThalidomideTriazolam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Triazolam.
TheophyllineThe therapeutic efficacy of Triazolam can be decreased when used in combination with Theophylline.
ThiamylalThe risk or severity of adverse effects can be increased when Triazolam is combined with Thiamylal.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Triazolam.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Triazolam.
ThiorphanThe serum concentration of Triazolam can be increased when it is combined with Thiorphan.
ThiothixeneThe risk or severity of adverse effects can be increased when Triazolam is combined with Thiothixene.
TiagabineThe risk or severity of adverse effects can be increased when Triazolam is combined with Tiagabine.
TiclopidineThe metabolism of Triazolam can be decreased when combined with Ticlopidine.
TiletamineThe risk or severity of adverse effects can be increased when Triazolam is combined with Tiletamine.
TipranavirThe serum concentration of Triazolam can be increased when it is combined with Tipranavir.
TizanidineThe risk or severity of adverse effects can be increased when Triazolam is combined with Tizanidine.
TocilizumabThe serum concentration of Triazolam can be decreased when it is combined with Tocilizumab.
TolcaponeThe risk or severity of adverse effects can be increased when Triazolam is combined with Tolcapone.
TopiramateThe risk or severity of adverse effects can be increased when Triazolam is combined with Topiramate.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Triazolam.
TrandolaprilThe serum concentration of Triazolam can be increased when it is combined with Trandolapril.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Triazolam is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Triazolam.
TrazodoneThe risk or severity of adverse effects can be increased when Triazolam is combined with Trazodone.
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Triazolam.
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Triazolam.
TrimipramineThe risk or severity of adverse effects can be increased when Triazolam is combined with Trimipramine.
TriprolidineThe risk or severity of adverse effects can be increased when Triazolam is combined with Triprolidine.
UbenimexThe serum concentration of Triazolam can be increased when it is combined with Ubenimex.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Triazolam.
VenlafaxineThe metabolism of Triazolam can be decreased when combined with Venlafaxine.
VerapamilThe metabolism of Triazolam can be decreased when combined with Verapamil.
VigabatrinThe risk or severity of adverse effects can be increased when Triazolam is combined with Vigabatrin.
VilazodoneThe risk or severity of adverse effects can be increased when Triazolam is combined with Vilazodone.
VildagliptinThe serum concentration of Triazolam can be increased when it is combined with Vildagliptin.
VoriconazoleThe metabolism of Triazolam can be decreased when combined with Voriconazole.
VortioxetineThe risk or severity of adverse effects can be increased when Triazolam is combined with Vortioxetine.
XimelagatranThe serum concentration of Triazolam can be increased when it is combined with Ximelagatran.
XylazineThe risk or severity of adverse effects can be increased when Triazolam is combined with Xylazine.
YohimbineThe therapeutic efficacy of Triazolam can be decreased when used in combination with Yohimbine.
ZaleplonThe risk or severity of adverse effects can be increased when Triazolam is combined with Zaleplon.
ZiconotideThe risk or severity of adverse effects can be increased when Triazolam is combined with Ziconotide.
ZimelidineThe risk or severity of adverse effects can be increased when Triazolam is combined with Zimelidine.
ZiprasidoneThe metabolism of Triazolam can be decreased when combined with Ziprasidone.
ZiprasidoneThe risk or severity of adverse effects can be increased when Triazolam is combined with Ziprasidone.
ZolazepamThe risk or severity of adverse effects can be increased when Triazolam is combined with Zolazepam.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Triazolam.
ZonisamideThe risk or severity of adverse effects can be increased when Triazolam is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Triazolam is combined with Zopiclone.
ZotepineThe risk or severity of adverse effects can be increased when Triazolam is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Triazolam is combined with Zuclopenthixol.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By si...
Gene Name:
GABRA1
Uniprot ID:
P14867
Molecular Weight:
51801.395 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA2
Uniprot ID:
P47869
Molecular Weight:
51325.85 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA3
Uniprot ID:
P34903
Molecular Weight:
55164.055 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA4
Uniprot ID:
P48169
Molecular Weight:
61622.645 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Transporter activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA5
Uniprot ID:
P31644
Molecular Weight:
52145.645 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA6
Uniprot ID:
Q16445
Molecular Weight:
51023.69 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By si...
Gene Name:
GABRB1
Uniprot ID:
P18505
Molecular Weight:
54234.085 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel.
Gene Name:
GABRB2
Uniprot ID:
P47870
Molecular Weight:
59149.895 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Gaba-gated chloride ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel.
Gene Name:
GABRB3
Uniprot ID:
P28472
Molecular Weight:
54115.04 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRG1
Uniprot ID:
Q8N1C3
Molecular Weight:
53594.49 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel.
Gene Name:
GABRG2
Uniprot ID:
P18507
Molecular Weight:
54161.78 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRG3
Uniprot ID:
Q99928
Molecular Weight:
54288.16 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Gaba-a receptor activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRD
Uniprot ID:
O14764
Molecular Weight:
50707.835 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRE
Uniprot ID:
P78334
Molecular Weight:
57971.175 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Gaba-a receptor activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel. In the uterus, the function of the receptor appears to be related to tissue contractility. The binding of this pI subunit with other GABA(A) receptor subunits alters the sensitivity of recombinant receptors to ...
Gene Name:
GABRP
Uniprot ID:
O00591
Molecular Weight:
50639.735 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Gaba-a receptor activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel. Rho-1 GABA receptor could play a role in retinal neurotransmission.
Gene Name:
GABRR1
Uniprot ID:
P24046
Molecular Weight:
55882.91 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Gaba-a receptor activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel. Rho-2 GABA receptor could play a role in retinal neurotransmission.
Gene Name:
GABRR2
Uniprot ID:
P28476
Molecular Weight:
54150.41 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Gaba-a receptor activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRR3
Uniprot ID:
A8MPY1
Molecular Weight:
54271.1 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Transmembrane signaling receptor activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRQ
Uniprot ID:
Q9UN88
Molecular Weight:
72020.875 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
other
General Function:
Cholesterol binding
Specific Function:
Can bind protoporphyrin IX and may play a role in the transport of porphyrins and heme (By similarity). Promotes the transport of cholesterol across mitochondrial membranes and may play a role in lipid metabolism (PubMed:24814875), but its precise physiological role is controversial. It is apparently not required for steroid hormone biosynthesis. Was initially identified as peripheral-type benz...
Gene Name:
TSPO
Uniprot ID:
P30536
Molecular Weight:
18827.81 Da
References
  1. Park CH, Carboni E, Wood PL, Gee KW: Characterization of peripheral benzodiazepine type sites in a cultured murine BV-2 microglial cell line. Glia. 1996 Jan;16(1):65-70. [PubMed:8787774 ]
Kind
Protein group
Organism
Human
Pharmacological action
yes
Actions
positive allosteric modulator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By similarity).
Components:
NameUniProt IDDetails
Gamma-aminobutyric acid receptor subunit alpha-1P14867 Details
Gamma-aminobutyric acid receptor subunit alpha-2P47869 Details
Gamma-aminobutyric acid receptor subunit alpha-3P34903 Details
Gamma-aminobutyric acid receptor subunit alpha-4P48169 Details
Gamma-aminobutyric acid receptor subunit alpha-5P31644 Details
Gamma-aminobutyric acid receptor subunit alpha-6Q16445 Details
Gamma-aminobutyric acid receptor subunit beta-1P18505 Details
Gamma-aminobutyric acid receptor subunit beta-2P47870 Details
Gamma-aminobutyric acid receptor subunit beta-3P28472 Details
Gamma-aminobutyric acid receptor subunit deltaO14764 Details
Gamma-aminobutyric acid receptor subunit epsilonP78334 Details
Gamma-aminobutyric acid receptor subunit gamma-1Q8N1C3 Details
Gamma-aminobutyric acid receptor subunit gamma-2P18507 Details
Gamma-aminobutyric acid receptor subunit gamma-3Q99928 Details
Gamma-aminobutyric acid receptor subunit piO00591 Details
Gamma-aminobutyric acid receptor subunit thetaQ9UN88 Details
References
  1. ChEMBL Compound Report Card [Link]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Williams JA, Ring BJ, Cantrell VE, Jones DR, Eckstein J, Ruterbories K, Hamman MA, Hall SD, Wrighton SA: Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metab Dispos. 2002 Aug;30(8):883-91. [PubMed:12124305 ]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23